258 related articles for article (PubMed ID: 16597592)
1. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Martino R; Iacobelli S; Brand R; Jansen T; van Biezen A; Finke J; Bacigalupo A; Beelen D; Reiffers J; Devergie A; Alessandrino E; Mufti GJ; Barge R; Sierra J; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; de Witte T;
Blood; 2006 Aug; 108(3):836-46. PubMed ID: 16597592
[TBL] [Abstract][Full Text] [Related]
2. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
3. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
4. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.
Martino R; Henseler A; van Lint M; Schaap N; Finke J; Beelen D; Vigouroux S; Alessandrino EP; Mufti GJ; Veelken JH; Bruno B; Yakoub-Agha I; Volin L; Maertens J; Or R; Leblond V; Rovira M; Kalhs P; Alvarez AF; Vitek A; Sierra J; Wagner E; Robin M; de Witte T; Kröger N
Bone Marrow Transplant; 2017 Aug; 52(8):1107-1112. PubMed ID: 28319072
[TBL] [Abstract][Full Text] [Related]
6. On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.
Campidelli A; Robin M; Remen T; Luc A; Labussière-Wallet H; Dulery R; Srour M; Ceballos P; Forcade E; Nguyen-Quoc S; Furst S; Turlure P; Bay JO; Simand C; Marçais A; Daguindau E; Rubio MT; D'Aveni M
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):34-43. PubMed ID: 34456160
[TBL] [Abstract][Full Text] [Related]
7. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
8. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
Bejanyan N; Zhang M; Bo-Subait K; Brunstein C; Wang H; Warlick ED; Giralt S; Nishihori T; Martino R; Passweg J; Dias A; Copelan E; Hale G; Gale RP; Solh M; Kharfan-Dabaja MA; Diaz MA; Ganguly S; Gore S; Verdonck LF; Hossain NM; Kekre N; Savani B; Byrne M; Kanakry C; Cairo MS; Ciurea S; Schouten HC; Bredeson C; Munker R; Lazarus H; Cahn JY; van Der Poel M; Rizzieri D; Yared JA; Freytes C; Cerny J; Aljurf M; Palmisiano ND; Pawarode A; Bacher VU; Grunwald MR; Nathan S; Wirk B; Hildebrandt GC; Seo S; Olsson RF; George B; de Lima M; Hourigan CS; Sandmaier BM; Litzow M; Kebriaei P; Saber W; Weisdorf D
Transplant Cell Ther; 2021 Jan; 27(1):68.e1-68.e9. PubMed ID: 33010430
[TBL] [Abstract][Full Text] [Related]
10. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
[TBL] [Abstract][Full Text] [Related]
11. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
12. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Kröger N; Iacobelli S; Franke GN; Platzbecker U; Uddin R; Hübel K; Scheid C; Weber T; Robin M; Stelljes M; Afanasyev B; Heim D; Deliliers GL; Onida F; Dreger P; Pini M; Guidi S; Volin L; Günther A; Bethge W; Poiré X; Kobbe G; van Os M; Brand R; de Witte T
J Clin Oncol; 2017 Jul; 35(19):2157-2164. PubMed ID: 28463633
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
Mohty M; Labopin M; Volin L; Gratwohl A; Socié G; Esteve J; Tabrizi R; Nagler A; Rocha V;
Blood; 2010 Nov; 116(22):4439-43. PubMed ID: 20716774
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
15. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
[TBL] [Abstract][Full Text] [Related]
16. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Scott BL; Pasquini MC; Fei M; Fraser R; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick E; Fernandez HF; Soiffer RJ; Alyea E; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Hourigan CS; Gui G; Mendizabal A; Horowitz MM; Deeg HJ; Horwitz ME
Transplant Cell Ther; 2021 Jun; 27(6):483.e1-483.e6. PubMed ID: 33775615
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Lim Z; Brand R; Martino R; van Biezen A; Finke J; Bacigalupo A; Beelen D; Devergie A; Alessandrino E; Willemze R; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; Kroger N; Mufti GJ; De Witte TM
J Clin Oncol; 2010 Jan; 28(3):405-11. PubMed ID: 20008642
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.
Sobecks RM; Leis JF; Gale RP; Ahn KW; Zhu X; Sabloff M; de Lima M; Brown JR; Inamoto Y; Hale GA; Aljurf MD; Kamble RT; Hsu JW; Pavletic SZ; Wirk B; Seftel MD; Lewis ID; Alyea EP; Cortes J; Kalaycio ME; Maziarz RT; Saber W
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1390-8. PubMed ID: 24880021
[TBL] [Abstract][Full Text] [Related]
19. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907
[TBL] [Abstract][Full Text] [Related]
20. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Estey E; de Lima M; Tibes R; Pierce S; Kantarjian H; Champlin R; Giralt S
Blood; 2007 Feb; 109(4):1395-400. PubMed ID: 17038533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]